Characterization of 'mini-nucleotides' as P2X receptor agonists in rat cardiomyocyte cultures. An integrated synthetic, biochemical, and theoretical study

Journal of Medicinal Chemistry

Volumn 42, Issue 14, 1999, Pages 2685-2696

  Fischer, Bilha ^a   Yefidoff, Revital ^a   Major, Dan T ^a   Rutman Halili, Irit ^a   Shneyvays, Valadimir ^a   Zinman, Tova ^a   Jacobson, Kenneth A ^b   Shainberg, Asher ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; NUCLEOTIDE DERIVATIVE; PURINE P2X RECEPTOR; PURINERGIC RECEPTOR STIMULATING AGENT; XANTHINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; DIPOLE; DRUG BINDING SITE; DRUG DESIGN; DRUG SYNTHESIS; HEART DISEASE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CALCIUM; CELLS, CULTURED; CRYSTALLOGRAPHY, X-RAY; LIGANDS; MODELS, MOLECULAR; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHORIC ACID ESTERS; RATS; RECEPTORS, PURINERGIC P2; STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINES;

EID: 0033566224     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990085i     Document Type: Article

References (59)

1. (a) Burnstock, G. Purinergic nerves. Pharmacol. Rev. 1972, 24, 509-81.
2. (b) King, B. F.; Townsend-Nicholson, A.; Burnstock, G. Metabotropic receptors for ATP and UTP: exploring the correspondence between native and recombinant nucleotide receptors. Trends Pharmacol. Sci. 1998, 19, 506-514.
3. (c) Chan, C. M.; Unwin, R. J.; Burnstock, G. Potential functional roles of extracellular ATP in kidney and urinary tract. Exp. Nephrol. 1998, 6, 200-207.
4. (d) Boaeder, M. R.; Hourani, S. M. O. The regulation of vascular function by P2 receptors: multiple site and multiple receptors. Trends Pharmacol. Sci. 1998, 19, 99-107.
5. (e) Barnard, E. A.; Simon, J.; Webb, T. E. Nucleotide receptors in the nervous system-An abundant component using diverse transduction mechanisms. Mol. Neurobiol. 1997, 15, 103-129.
6. (f) Inoue, K. The function of ATP receptors in the hippocampus. Pharmacol. Res. 1998, 38, 323-331.
7. (g) Abbrachio, M. P. P1 and P2 receptors in cell growth and differentiation. Drug Dev. Res. 1996, 39, 393-406.
8. (a) Spedding, M.; Williams, M. Development in purine and pyrimidine receptors based therapeutics. Drug Dev. Res. 1996, 39, 436-441.
9. (b) Abbracchio, M. P.; Burnstock, G. Purinoceptore: are there families of P2X and P2Y Purinoceptors? Pharmacol. Ther. 1994, 64, 445-475.
10. (c) Barnard, E. A.; Burnstock, G.; Webb, T. E. The G-protein coupled receptors for ATP and other nucleotides: a new receptor family. Trends Pharmacol. Sci. 1994, 15, 67-70.
11. 2+ concentration in isolated rat ventricular myocytes. J. Physiol 1992, 445, 369-388.
12. 2+ transients in cardiac myocytes which are potentiated by norepinephrine. FEBS Lett. 1987, 223, 53-58.
13. 2+ mobilization by extracellular ATP in rat cardiac myocytes: regulation by protein kinase C and A. Am. J. Physiol. 1992, 263, C933-C940.
14. (d) Bogdanov, Y.; Rubino, A.; Burnstock, G. Characterisation of subtypes of the P2X and P2Y families of ATP receptors in the foetal human heart. Life Sci. 1998, 62, 697-703.
15. Bjornsson, O. G.; Monck, J. R.; Williamson, J. R. Identification of P2Y purinoceptors associated with voltage-activated cation channels from cardiac ventricular myocytes of the rat. J. Biochem. 1989, 186, 395-404.
16. Hohl, C. M.; Hearse, D. J. Vascular and contractile responses to extracellular ATP: studies in the isolated rat heart. Can. J. Cardiol. 1985, 1, 207-216.
17. (a) Fischer, B.; Boyer, J. L.; Hoyle, C. H. V.; Ziganshin, A. V.; Brizzolara, A. L.; Knight, G. E.; Zimmet, J.; Burnstock, G.; Harden, T. K.; Jacobson, K. A. Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5′-triphosphate. J. Med. Chem. 1993, 36, 3937.
18. (b) Burnstock, G.; Fischer, B.; Hoyle, C. H. V.; Maillard, M.; Ziganshin, A. V.; Brizzolara, A. L.; von Isakovics, A.; Boyer, J. L.; Harden, T. K.; Jacobson, K. A. Structure activity relationship for derivatives of adenosine 5′-triphosphate as agonists at P2-purinoceptors: heterogeneity within P2X and P2Y subtypes. Drug Dev. Res. 1994, 31, 206.
19. (c) Boyer, J. L.; O'Tuel, J. W.; Fischer, B.; Jacobson, K. A.; Harden, T. K. 2-Thioether derivatives of adenine nucleotides are exceptionally potent agonists at adenylyl cyclase-linked P2Y-purinoceptors. Br. J. Pharmacol. 1995, 116, 2611.
20. 1 receptor ligands-a test case for distributed multipole analysis in medicinal chemistry. J. Comput. Aided Mol. Des. 1995, 9, 44-54 and references therein.
21. (a) Marzilli, L. G.; Epps, L. A.; Sorrell, T.; Kistenmacher, T. Reaction of coordinated purines. A facile, high yield synthetic route to N7-alkylated xanthines and hypoxanthines. The structure of [bis(dimethylglyoximato) (xanthinato)-(tri-n-butylphosphine) cobalt (III)] and the trans influence in cobalt (III) chemistry. J. Am. Chem. Soc. 1975, 97, 3351.
22. (b) Daly, J. W.; Hide, I.; Mueller, C. E.; Shamim, M. Caffeine analogues: Structure-activity relationships at adenosine receptors. Pharmacology 1991, 42, 309-321.
23. (a) Lister, J. H. In Fused pyrimidines Part II: purines; Wiley Interscience: New York, 1971.
24. (b) Cottam, H. B.; Shih, H.; Tehrani, L. R.; Wasson, D. B.; Carson, D. Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor α. J. Med. Chem. 1996, 39, 2-9.
25. (a) Mandai, S. B.; Giri, V. S.; Pakrashi, S. C. Sodium borohydride desulfurization of thiolactams to amines. Heterocycles, 1988, 27, 11.
26. (b) Soai, K.; Oyamada, H.; Ookawa, A. Sodium borohydride tert-butyl alcohol-methanol as an efficient system for the selective reduction of esters. Synth. Commun. 1982, 12, 463-467.
27. Gingras, M.; Chan, T. H. Silver-assisted reactions of organotin oxides. A mild, neutral and anhydrous one-step conversion of primary organic halides to alcohols. Tetrahedron Lett. 1989, 30, 279-282.
28. (a) Kovacs, T.; Otvos, L. Simple synthesis of 5-vinyl- and 5-ethenyl-2′-deoxyuridine-5′-triphosphates. Tetrahedron Lett. 1988, 29, 4525-4528.
29. (b) Moffat, J. G. A general synthesis of nucleoside 5′-triphosphates. Can. J. Chem. 1964, 42, 599.
30. Kopel, H. C.; Springer, R. H.; Robins, R. K.; Schneider, F. H.; Cheng, C. C. Synthesis of some 8-substituted bis(β-chloroethyl)-amino derivatives of naturally occurring N-methylated purines. J. Org. Chem. 1962, 27, 2173.
31. Fischer, B. Therapeutic applications of ATP-(P2)-receptors agonists and antagonists. Expert. Opin. Ther. Pat. 1999, 9, 385-399.
32. (a) Lambrecht, G.; Ardanuy, U.; Baumert, H. G.; Bo, X.; Hoyle, C. H. V.; Nickel, P.; Pfaff, O.; Ralevic, V.; Windschief, U.; Ziganshin, A. U.; Ziyal, R.; Mutscheler, E.; Burnstock, G. Design and Pharmacological characterization of selective P2-purinoceptor antagonists. In Perspectives in Receptor Research; Pharmaco Chemistry Library, Giardina, D., Piergentili, S., Pigini, M., Eds.; Elsevier Science Publishers: Amsterdam, 1996; pp 337-350.
33. (b) Boyer, J. L.; Zohn, I. E.; Jacobson, K. A.; Harden, T. K. Differential effects of P2-purinergic receptor antagonists on phospholipase C and adenylyl cyclase-coupled P2Y purinergic receptors. Br. J. Pharmacol. 1994, 113, 614-620.
34. (c) Harden, T. K.; Nicholas, R. A.; Schachter, J. B.; Lazarowski, E.; Boyer, J. L. Pharmacological selectivities of molecularly defined subtypes of P2Y receptors. In The P2 Nucleotide Receptors; Turner, J. T., Weisman, G., Fedan, J., Eds.; The Receptors; Humana Press: Clifton, NJ, 1997; Chapter 5, pp 109-134.
35. (d) Evans, R. J.; Surprenant, A.; North, R. A. P2X receptors. In The P2 Nucleotide Receptors; Turner, J. T., Weisman, G., Fedan, J., Eds.; The receptors; Humana Press: Clifton, NJ, 1997; Chapter 2, pp 43-61.
36. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
37. (a) Binkley, J. S.; Pople, J. A.; Hehre, W. J. Self-consistent molecular orbital methods. 21. Small split-valence basis sets for first-row elements. J. Am. Chem. Soc. 1980, 102, 939-947.
38. (b) Gordon, M. S.; Binkley, J. S.; Pople, J. A.; Pietro, W. J.; Hehre, W. J. Self-consistent molecular orbital methods. 22. Small splitvalence basis sets for second-row elements. J. Am. Chem. Soc. 1982, 104, 2797-2803.
39. (c) Pietro, W. J.; Francl, M. M.; Hehre, W. J.; DeFrees, D. J.; Pople, J. A.; Binkley, J. S. Self-consistent molecular orbital methods. 24. Supplemented small split-valence basis sets for second-row elements. J. Am. Chem. Soc. 1982, 104, 5039-5048.
40. Hehre, W. J.; Radom, L.; Schleyer, P. V. R.; Pople, J. A. Ab Initio molecular orbital theory; Wiley: New York, 1986; Chapter 6.
41. Weiler-Feilchenfeld, H.; Bergmann, E. D. The dipole moments of some purine and pyrimidine derivatives. Israel J. Chem. 1968, 6, 823-826.
42. (a) Naray-Szabo, G.; Ferenczy, G. G. Molecular Electrostatics. Chem. Rev. 1995, 95, 829-847.
43. (b) Doucet, J.-P.; Weber, J. Computer-Aided Molecular Design: Theory and Applications; Academic Press Inc.: San Diego, CA, 1996; Chapter 10.
44. Pauling, L. Proc. Natl. Acad. Sci. U.S.A. 1928, 14, 359.
45. Politzer, P., Murray, J. S., Lipkowitz, K. B., Boyd, D. B., Eds. Molecular electrostatic potentials and chemical reactivity. Reviews in Computational Chemistry; VCH: New York 1991: Vol. 2, Chapter 7, pp 273-312.
46. Kahn, S. D.; Pau, C. F.; Hehre, W. J. Models for chemical reactivity: Mapping of intermolecular potentials onto electron density surfaces. Int. J. Quantum Chem., Quantum Chem. Symp. 1988, 22, 575-591.
47. Sjoberg, P.; Murray, J. S.; Brinck, T.; Evans, P.; Politzer, P. The use of the electrostatic potential at the molecular surface in recognition interactions: dibenzo-p-dioxins and related Systems. J. Mol. Graphics 1990, 8, 81-85.
48. Nobeli, I.; Price, S. L.; Lommerse, J. P. M.; Taylor, R. Hydrogen bonding properties of oxygen and nitrogen acceptors in aromatic heterocycles. J. Comput. Chem. 1997, 18, 2060-2074.
49. Hansen, M. A.; Balcar, V. J.; Barden, J. A.; Bennett, M. R. Localisation of P2X subtypes in heart, artery and bladder. Drug Dev. Res. (Special issue, 6th International Symposium on Adenosine and Adenine Nucleotides.) 1998, 43, 5.
50. Webb, T. E.; Boluyt, M. O.; Barnard, E. A. Molecular biology of P2Y purinoceptors: Expression in rat heart. J. Auton. Pharmacol. 1996, 16, 303-307.
51. Shryock, J. C.; Belardinelli, L. Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology and pharmacology. Am. J. Cardiol. 1997, 79, 2-10.
52. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc. Res. 1998, 37, 279-289.
53. Hansen, M. A.; Barden, J. A.; Balcar, V. J.; Keay, K. A.; Bennett, M. R. Structural motif and characteristics of the extracellular domain of P2X receptors. Biochem. Biophys. Res. Commun. 1997, 236, 670-675.
54. 1 adenosine receptors by amiodarone and electrical stimulation in rat myocardial cells in vitro. Biochem. Pharmacol. 1997, 54, 583-587.
55. Zangen, A.; Shainberg, A. Thiamine deficiency in cardiac cells in culture. Biochem. Pharmacol. 1997, 54, 575-582.
56. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260, 3440-3450.
57. Gaussian 94, Gaussian Inc.; Pittsburgh, PA.
58. PC Spartan 1.0, Wavefunction Inc., Irvine, CA.
59. Manoach, M.; Varon, D.; Shainberg, A.; Zinman, T.; Isaack, A.; Halili-Rutman, I.; Kaplan D.; Tribulova N. The protective effect of class III antiarrhythmic agents against calcium overload in cultured myocytes. Life Sci. 1997, 61, PL 227-234.